Literature DB >> 8443964

Molecular analysis of C3 allotypes in patients with nephritic factor.

J E Finn1, P W Mathieson.   

Abstract

The autoantibody nephritic factor (NeF) leads to complement consumption in vivo and is associated with type II mesangiocapillary glomerulonephritis (MCGN II) and partial lipodystrophy (PLD). The third component of complement (C3) exists in two common allotypic forms, C3S and C3F, distinguished at the protein level by electrophoresis. An increased frequency of the rarer C3F allele has been reported in several autoimmune conditions, including one small series of patients with NeF. However, patients with NeF have low levels of circulating C3 so that allotyping at the protein level is difficult. The molecular basis of the S/F polymorphism has recently been established: a single base change at the DNA level encodes a single amino acid substitution at the protein level. A second polymorphism, closely linked to the first, is defined by the MoAb HAV 4-1, and is also due to a single base change. These polymorphisms can therefore be analysed at the DNA level. We have used the amplification refractory mutation system (ARMS), a modification of the polymerase chain reaction (PCR), to analyse these two C3 polymorphisms at the DNA level in 26 patients with NeF. The allele frequencies of C3S and C3F were 0.673 and 0.327 (predicted values 0.79 and 0.2, chi 2 = 4.813, P < 0.05), giving a relative risk of 2.1 for the development of NeF conferred by the presence of a C3F allele. The HAV 4-1 allele frequencies were (-) 0.71 and (+) 0.29, i.e. not significantly different than predicted from the linked C3S/F allele frequencies. This is the largest series of patients with NeF yet published, and our data confirm an association between C3F and NeF. Possible mechanisms for for this link are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443964      PMCID: PMC1554701          DOI: 10.1111/j.1365-2249.1993.tb05917.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

Review 1.  The immunogenetic basis of autoimmunity.

Authors:  D B Oliveira; D K Peters
Journal:  Autoimmunity       Date:  1990       Impact factor: 2.815

2.  The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.

Authors:  M R Daha; K F Austen; D T Fearon
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

3.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

4.  Heterogeneity of nephritic factor and its identification as an immunoglobulin.

Authors:  A E Davis; J B Ziegler; E W Gelfand; F S Rosen; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

5.  Capacity of complement c3 phenotypes to bind on to mononuclear cells in man.

Authors:  H Arvilommi
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

6.  The isolation of high molecular weight DNA from whole organisms or large tissue masses.

Authors:  D E Graham
Journal:  Anal Biochem       Date:  1978-04       Impact factor: 3.365

7.  The complement abnormalities of lipodystrophy.

Authors:  J G Sissons; R J West; J Fallows; D G Williams; B J Boucher; N Amos; D K Peters
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

8.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

9.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

10.  Genetic polymorphism of the third component of human complement (C'3).

Authors:  C A Alper; R P Propp
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

View more
  17 in total

Review 1.  Molecular pathology of age-related macular degeneration.

Authors:  Xiaoyan Ding; Mrinali Patel; Chi-Chao Chan
Journal:  Prog Retin Eye Res       Date:  2008-11-06       Impact factor: 21.198

2.  Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.

Authors:  Meike Heurich; Ruben Martínez-Barricarte; Nigel J Francis; Dawn L Roberts; Santiago Rodríguez de Córdoba; B Paul Morgan; Claire L Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

3.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

Review 4.  Complement, age-related macular degeneration and a vision of the future.

Authors:  Karen M Gehrs; Jared R Jackson; Eric N Brown; Rando Allikmets; Gregory S Hageman
Journal:  Arch Ophthalmol       Date:  2010-03

5.  C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis.

Authors:  U Persson; L Truedsson; K W Westman; M Segelmark
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 6.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

7.  R102G polymorphism of the C3 gene associated with exudative age-related macular degeneration in a French population.

Authors:  Jennyfer Zerbib; Florence Richard; Nathalie Puche; Nicolas Leveziel; Salomon Y Cohen; Jean-François Korobelnik; José Sahel; Arnold Munnich; Josseline Kaplan; Jean-Michel Rozet; Eric H Souied
Journal:  Mol Vis       Date:  2010-07-15       Impact factor: 2.367

8.  Molecular characterization of the pig C3 gene and its association with complement activity.

Authors:  Klaus Wimmers; Supamit Mekchay; Karl Schellander; Siriluck Ponsuksili
Journal:  Immunogenetics       Date:  2003-01-09       Impact factor: 2.846

Review 9.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

10.  C3 R102G polymorphism increases risk of age-related macular degeneration.

Authors:  Kylee L Spencer; Lana M Olson; Brent M Anderson; Nathalie Schnetz-Boutaud; William K Scott; Paul Gallins; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Hum Mol Genet       Date:  2008-03-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.